Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Assembly Biosciences (ASMB) Gains from Investment Securities: 2015-2024

Historic Gains from Investment Securities for Assembly Biosciences (ASMB) over the last 10 years, with Dec 2024 value amounting to $2.0 million.

  • Assembly Biosciences' Gains from Investment Securities was N/A to $225,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $225,000, marking a year-over-year change of. This contributed to the annual value of $2.0 million for FY2024, which is 19.49% down from last year.
  • According to the latest figures from FY2024, Assembly Biosciences' Gains from Investment Securities is $2.0 million, which was down 19.49% from $2.4 million recorded in FY2023.
  • Assembly Biosciences' 5-year Gains from Investment Securities high stood at $4.7 million for FY2020, and its period low was -$4.7 million during FY2021.
  • For the 3-year period, Assembly Biosciences' Gains from Investment Securities averaged around $1.2 million, with its median value being $2.0 million (2024).
  • In the last 5 years, Assembly Biosciences' Gains from Investment Securities tumbled by 199.60% in 2021 and then skyrocketed by 400.00% in 2023.
  • Over the past 5 years, Assembly Biosciences' Gains from Investment Securities (Yearly) stood at $4.7 million in 2020, then plummeted by 199.60% to -$4.7 million in 2021, then soared by 82.64% to -$814,000 in 2022, then surged by 400.00% to $2.4 million in 2023, then fell by 19.49% to $2.0 million in 2024.